Hikma launches exclusive distribution of Claritag® skin tag removal device in MENA

JORDAN — Hikma Pharmaceuticals PLC, the multinational pharmaceutical leader, has entered into an exclusive licensing agreement with DGI Group LLC, a US-based company known for professional and commercial medical equipment and supplies.

 This deal authorizes Hikma to exclusively market Claritag®, a cutting-edge over-the-counter (OTC) device for skin tag removal, throughout the MENA region.

Claritag® utilizes a patented Squeeze & Freeze® technology, providing a fast and effective way for adults aged 21 and older to remove skin tags safely at home.

The device employs an innovative treatment that causes skin tags to detach naturally within seven to fourteen days, offering a non-invasive solution trusted and recommended by dermatologists.

Designed for ease of use, Claritag® requires no assembly, delivering an affordable and convenient alternative to visiting a dermatologist.

It suits all skin types and tones, effectively targeting skin tags while avoiding damage to surrounding skin.

The device’s medical-grade formulation ensures reliable results in a user-friendly format.

Mazen Darwazah, Hikma’s Executive Vice Chairman and President of MENA, expressed enthusiasm about the partnership, emphasizing the company’s commitment to expanding its Consumer Health portfolio.

By introducing Claritag® to the region, Hikma aims to provide consumers with an innovative and accessible option for a common skin concern.

He further highlighted that Claritag® aligns with Hikma’s goal to offer safe, dermatologist-tested health products that meet the everyday needs of patients and local communities.

This new addition complements Hikma’s ongoing efforts to diversify consumer healthcare offerings and improve access to high-quality, innovative health solutions.

The collaboration marks a strategic advancement for Hikma in the consumer health sector, reflecting its dedication to delivering practical healthcare products across the MENA region.